_1746246418 20250503042658000 Rovedar Daryoushbabazadeh@gmail.com Rovedar Journal of Lab Animal Research J Lab Anim. Res 2980-9703 10 31 2024 3 5 Kalpana Sen https://orcid.org/0009-0000-7138-2868 Trilochan Satapathy https://orcid.org/0000-0001-6871-1288 Diabetes Mellitus (DM) is a multitudinous metabolic disorder that can occur due to insufficient or inefficient levels of insulin that leads to hyperglycemia. In many conditions, diabetes can also directly or indirectly lead to other functional disorders such as dyslipidemia and hypertension making them more severe and life-threatening. It is believed that Type 1 Diabetes can be caused by to process of auto-immune destruction of beta-cells of Islet of Langerhans of the pancreas responsible for the production of insulin whereas Type 2 diabetes is because of resistance against insulin along with the futilities of beta-cells to compensate the body with the required amount of insulin. The animal models are considered an essential component in the experimental studies and drug discovery process. Animal models provide safety, effectiveness, and dose of the test substance that needs to be extrapolated to human use. There are several methods for the induction of diabetes in experimental animal models. The present review aimed to discuss and explore currently used approaches including models from streptozotocin-induced diabetes to transgenic models for reproducible and safe diabetes induction in different experimental animals (rats, mice, guinea pigs, and dogs) and sex. Additionally, some genetically modified animal models are also included and discussed in this review which will pave the way for further studies.   10 31 2024 27 39 https://creativecommons.org/licenses/by/4.0 10.58803/jlar.v3i5.47 https://jlar.rovedar.com/index.php/JLAR/article/view/47 https://jlar.rovedar.com/index.php/JLAR/article/download/47/96 https://jlar.rovedar.com/index.php/JLAR/article/download/47/96 Mishra G, Panda PK et al. Animal models for type 2 diabetes: A review. World Journal of Pharmaceutical Sciences. 2016: 141-7. Kottaisamy CPD, Raj DS et al. Experimental animal models for diabetes and its related complications-a review. Lab Anim Res. 2021; 37(1):23. DOI: 10.1186/s42826-021-00101-4 10.4066/AMJ.2014.1979 10.1186/s12992-014-0080-x 10.1016/j.diabres.2017.03.024 10.5530/ijper.51.4s.79 Athmuri DN, Shiekh PA. Experimental diabetic animal models to study diabetes and diabetic complications. MethodsX. 2023; 11: 102474. DOI-10.1538/expanim1978.29.1_1. Sharma P, Garg A et al. Animal model used for experimental study of diabetes mellitus: an overview. Asian J. Biomater. Res. 2016; 2: 99–110. Bryda EC. The mighty mouse: the impact of rodents on advances in biomedical research.Mol. Med. 2013; 110: 207. 10.1007/s40200-023-01277-3 10.5530/pj.2017.1.7 10.1016/S0083-6729(08)60833-X 10.1258/ebm.2012.011372 10.31489/2023bmg3/206-215 Trivedi NA, Mazumdar B, et al. Effect of shilajit on blood glucose and lipid profile in alloxan-induced diabetic rats. Indian journal of pharmacology. 2004; 36(6):373-6. 10.1002/ijc.2910350316 10.15406/japlr.2016.03.00071 10.1038/s41598-019-49547-6 10.1002/dmrr.2486 10.1248/bpb.b15-00842 10.33549/physiolres.930111 Rakieten N, Rakieten ML et al. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep. 1963; 29:91-8. Satapathy T, Chitra KS et al. Single dose drug interaction study between anti-hypertensive drug valsartan on anti-diabetic effect of sulphonylureas in normal and streptozotocin induced diabetic rats. International Journal of Medicobiological Research. 2013; 1(7): 356-360. 10.1038/laban0209-55 10.1556/APhysiol.101.2014.4.2 10.31254/phyto.2014.3201 Arulmozhi DK, Veeranjaneyulu A et al. Neonatal streptozotocin-induced rat model of Type 2 diabetes mellitus: A glance. Indian Journal of Pharmacology. 2004; 36(4):217. DOI-10.1155%2F2014%2F463264. 10.1016/j.phrs.2005.05.004 10.1007/978-3-642-65232-5_6 10.1007/BF00245832 10.1016/0006-2952(82)90571-8 10.1001/jama.1943.02840340013004 10.1055/s-2007-1002058 10.1210/endo-33-5-297 Maqbool M, Dar MA et al. Animal models in diabetes mellitus: an overview. Journal of Drug Delivery and Therapeutics. 2019; 9(1-s):472-5. DOI-10.22270/jddt.v9i1-s.2351. 10.1016/j.dld.2006.02.007 10.2337/db07-1294 10.1097/00007890-198612000-00022 10.1007/s00125-008-0969-0 10.1016/j.ajme.2017.05.011 10.22270/jddt.v9i1-s.2351 10.2337/db12-0848 10.1097/01.sla.0000102989.54824.fc 10.2337/diabetes.37.6.723 10.3892/etm.2014.1832 10.1152/ajpendo.00099.2002 10.1007/978-1-62703-068-7_10 10.1007/BF01221634 10.1258/002367785780893575 10.1201/9781420009453.ch15 10.1620/tjem.119.85 10.1507/endocrj.45.737 10.1385/1-59259-392-5:29 10.1186/1475-2840-11-9 10.2337/diab.41.11.1422 10.2337/diabetes.41.4.476 10.1016/0014-4800(73)90040-3 Shafrir EL, Sima AA. Diabetic animals for research into the complications: A general overview. Chronic complications in diabetes. Frontiers in animal diabetes research. 2000; 1:1-42. 10.1096/fasebj.5.8.2022312 10.1530/jrf.0.0130041 10.1507/endocrj1954.17.23 10.2220/biomedres.6.103 10.2337/diabetes.46.5.887 10.1126/science.153.3740.1127 10.1016/S0021-9150(00)00406-8 10.2337/diabetes.34.12.1217 10.1007/s001250051614 10.1128/JVI.77.10.5649-5656.2003 10.1038/nm0798-781 10.17925/EE.2020.16.1.25 10.1038/164209a0 10.1210/endo-39-1-32 10.1371/journal.pone.0066139 10.3791/56672-v 10.1371/journal.pone.0030555 10.1038/nrendo.2009.275 10.1042/bj0590179 10.1016/0002-9343(61)90031-6 10.1007/978-94-009-4171-7_5 10.1016/S0065-2776(08)60274-6 10.1186/s42826-021-00101-4 10.1016/j.mex.2023.102474 10.2741/3816 10.1016/j.sjopt.2018.05.002 10.1007/s00592-010-0180-x 10.3748/wjg.v13.i2.175 10.4239/wjd.v1.i5.141 10.3390/ijms21249456 10.1007/s12325-014-0140-x